Multiple myeloma (MM) is a blood cancer that forms in plasma cells. These cancerous cells accumulate in bone marrow, where they produce abnormal monoclonal antibodies (mAb), rather than helpful infection-fighting antibodies. Administering therapeutic mAbs are an emerging therapy for MM, as well as for other MM comorbidities. However, the foreign mAbs may result in false positive results, leading to additional unnecessary and lengthy treatments, as well as continued treatment in the absence of MM or a preemptive diagnosis of partial or complete remission. Finding a way to detect and measure abnormal mAb without interference from their therapeutic counterparts is necessary in order to effectively utilize emerging therapeutic mAb treatments.
Description
Diagnosis of MM and measurements of treatment efficacy rely on total protein electrophoresis (TPE), which measures mAb concentration, and immunofixation electrophoresis (IFE), which identifies the clone subtype. Therapeutic mAbs cause false positive interference in TPE and IFE testing, which can prolong unnecessary treatment or additional tests, including bone marrow biopsies. By coating magnetic beads with an antigen targeted to the therapeutic mAbs, they can be depleted before patient testing. This method allows for more robust diagnostic and treatment efficacy protocols and eliminates the chances of false positives. This treatment is accessible for any antibody with a known antigen, and beads can be coated with multiple antigens to be used for any patient on FDA-approved monoclonal antibody therapy or as part of a clinical trial therapy.
Applications
· Eliminating false positives in multiple myeloma diagnostic tests for patients on mAb therapies
· Clarifying results in treatment monitoring measurements for patients on mAb therapies
· Eliminates unnecessary continued treatment after MM remission
Advantages
· Can use with any antibody with a known antigen
· Antigens can be mixed and deployed simultaneously, creating a single reagent for all approved mAb therapies
· Testing does not require a corresponding patient control, reducing total testing to improve laboratory efficiency
· Allows for accurate quantification of patient disease in TPE
Invention Readiness
In vitro data
IP Status
https://patents.google.com/patent/US20220187309A1
